ホーム › 非小細胞肺癌 › カリフォルニア州 › Orange
Orange、CAにおける非小細胞肺癌の臨床試験
Orangeとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
被験者募集中第2/3相
- Providence St. Joseph Hospital, Orange
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- University of California, Irvine Health, Orange
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- University of California Irvine, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
- University of California Irvine, Orange
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1相
- University of California - Irvine, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- UC IRVINE Health, Orange
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- University of California Irvine Medical Center, Orange
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Orange
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
被験者募集中第3相
- University of California Irvine, Orange
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- Providence St. Joseph Hospital, Orange
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
被験者募集中第1/2相
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Orange
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
被験者募集中第3相
- UCI Chao Family Comprehensive Cancer Center, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
被験者募集中第1相
- Research Site, Orange
A Study of VET3-TGI in Patients With Solid Tumors
被験者募集中第1相
- UC Irvine Health, Orange
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
被験者募集中観察研究
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Orange
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Orangeにおける他の研究
- 転移性癌20件の研究
- 大腸癌16件の研究
- 卵巣がん16件の研究
- 膵臓がん15件の研究
- 悪性黒色腫14件の研究
- 肝臓がん（肝細胞がん）14件の研究
- 乳がん14件の研究
- 肺がん14件の研究
- 前立腺がん14件の研究
- 胃癌13件の研究
- がん（全種類）13件の研究
- 急性骨髄性白血病13件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。